<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04937803</url>
  </required_header>
  <id_info>
    <org_study_id>LPCTP-2020-001</org_study_id>
    <nct_id>NCT04937803</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Drug-Coated Balloon for De-novo Lesions in Patients With Acute Coronary Syndromes (DCB-ACS)</brief_title>
  <acronym>DCB-ACS</acronym>
  <official_title>Safety and Efficacy of Drug-Coated Balloon for De-novo Lesions in Patients With Acute Coronary Syndromes (DCB-ACS): A Prospective, Multi-Center, Randomized-Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daqing Oil Field Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sichuan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third Affiliated Hospital of Chinese Pla General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jining Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fuwai Central China Cardiovascular Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital of Taiyuan Iron &amp; Steel Company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inner Mongolia People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Harbin Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The DCB-ACS trial is a prospective, multi-center, non-inferiority, randomized controlled&#xD;
      trail. The purpose of this trial is to evaluate the safety and efficacy of drug-coated&#xD;
      balloon(DCB) in de novo lesions for acute coronary syndromes (ACS) .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with ACS and indications for percutaneous coronary intervention were randomly&#xD;
      assigned (1:1) to receive angioplasty with DCB or implantation of a Zotarolimus-Eluting&#xD;
      Coronary Stent(ZES) . Dual anti-platelet therapy was given according to current guidelines.&#xD;
      Follow-up was originally scheduled at by telephone or clinical visit at 1 month, 6 months, 12&#xD;
      months, and 24 months after discharge, and coronary angiography and FFR measurements will be&#xD;
      carried out at 9 months.The primary objective is to show non-inferiority of DCB versus&#xD;
      drug-eluting stent(DES) regarding the functional assessment of target lesion by FFR at 9&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fractional flow reserve (FFR)</measure>
    <time_frame>9 months follow-up</time_frame>
    <description>Fractional flow reserve is the ratio of mean coronary pressure distal of the treated lesion to mean aortic pressure during maximum hyperemia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure（TLF）</measure>
    <time_frame>1 month, 6 months, 9 months, 12 months, 24 months follow-up</time_frame>
    <description>A composite endpoint consisting of cardiac death, target vessel-related myocardial infarction, and revascularization of target lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>1 month, 6 months, 9 months, 12 months, 24 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel-related myocardial infarction</measure>
    <time_frame>12 months, 24 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revascularization of target lesion revascularization (TLR)</measure>
    <time_frame>1 month, 6 months, 9 months, 12 months, 24 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death and myocardial infarction</measure>
    <time_frame>1 month, 6 months, 9 months, 12 months, 24 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>1 month, 6 months, 9 months, 12 months, 24 months follow-up</time_frame>
    <description>Defined as Bleeding Academic Research Consortium type 3 to 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure success</measure>
    <time_frame>1 month</time_frame>
    <description>Including device success, lesion success and procedure success</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-oriented composite endpoint (PoCE)</measure>
    <time_frame>1 month, 6 months, 9 months, 12 months ,24 months follow-up</time_frame>
    <description>A composite of all-cause mortality, myocardial infarction, and any revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diameter stenosis(DS%)</measure>
    <time_frame>9 months follow-up</time_frame>
    <description>DS% defined as: (1 - minimal luminal diameter /reference vessel diameter) *100%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late lumen loss (LLL）</measure>
    <time_frame>9 months follow-up</time_frame>
    <description>The difference between the in-segment minimal lumen diameter after the procedure and at angiographic follow-up, as evaluated by quantitative coronary angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Restenosis rate of target lesion</measure>
    <time_frame>9 months</time_frame>
    <description>Diameter stenosis %≥50%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite and possible thrombotic events</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehospitalized due to angina</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>2 years</time_frame>
    <description>Diagnosed by a neurologist</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">212</enrollment>
  <condition>Drug-Coated Balloon</condition>
  <condition>De Novo Stenosis</condition>
  <condition>Acute Coronary Syndromes</condition>
  <condition>ACS</condition>
  <condition>DCB</condition>
  <condition>Clinical Trial</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Drug-coated balloon group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to drug-coated balloon group will receive angioplasty with drug-coated balloon for treatment of lesions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stent group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients assigned to drug-eluting stent group will receive a Zotarolimus -Eluting Coronary Stent treatment .</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug-coated balloon</intervention_name>
    <description>Drug-coated balloon is a fast-exchange balloon dilatation catheter, used to treat coronary artery stenosis lesions and improve myocardial blood flow.</description>
    <arm_group_label>Drug-coated balloon group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Zotarolimus-Eluting Coronary Stent</intervention_name>
    <description>Zotarolimus-Eluting Coronary Stent is treated for coronary artery stenosis lesions .</description>
    <arm_group_label>Stent group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age≥18 Years and &lt;80 years;&#xD;
&#xD;
          2. ACS patients eligible for percutaneous coronary intervention;&#xD;
&#xD;
          3. Successful preparation is defined as ≤ 30% residual stenosis with Thrombolysis in&#xD;
             Myocardial Infarction (TIMI) Grade III flow and not evidence of type C-F dissection;&#xD;
&#xD;
          4. Vessel diameter from 2.25mm-4.0 mm ;&#xD;
&#xD;
          5. Lesion length ≤ 28 mm;&#xD;
&#xD;
          6. A single culprit lesion or 1 lesion in each of two vessels ;&#xD;
&#xD;
          7. Eligible for enrollment and provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Clinical Exclusion Criteria：&#xD;
&#xD;
          1. Stable angina or asymptomatic myocardial ischemia;&#xD;
&#xD;
          2. Cardiogenic shock or requiring mechanical support for breathing and circulation;&#xD;
&#xD;
          3. Hemodynamically unstable tachyarrhythmia or bradyarrhythmia;&#xD;
&#xD;
          4. Plan to perform cardiac surgery or non-cardiac surgery within 24 months of&#xD;
             percutaneous coronary intervention;&#xD;
&#xD;
          5. A history of stroke within 6 months;&#xD;
&#xD;
          6. History of severe renal insufficiency;&#xD;
&#xD;
          7. Life expectancy &lt; 12 months;&#xD;
&#xD;
          8. Pregnant women;&#xD;
&#xD;
          9. Allergies to aspirin, clopidogrel, ticagrelor, heparin, contrast agents, and&#xD;
             paclitaxel, patients with systemic lupus erythematosus or other systemic immune&#xD;
             diseases;&#xD;
&#xD;
         10. Patients not suitable for enrollment considered by researcher;&#xD;
&#xD;
         11. Currently participating in another trial before reaching the primary endpoint;&#xD;
&#xD;
         12. Inability to provide informed consent. Image Exclusion Criteria&#xD;
&#xD;
        1. Chronic total occlusion (CTO); 2. Left main lesion; 3. Bifurcation lesions treated with&#xD;
        double stents; 4. Moderate to severe distortion, angulation or severe calcification&#xD;
        lesions; 5. Coronary artery graft stenosis; 6. In-stent restenosis; 7. To be&#xD;
        re-hospitalized for the other scheduled PCI treatment; 8. Myocardial bridge at the target&#xD;
        lesion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Yu, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Second Affiliated Hospital of Harbin Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haibo Jia, MD,PhD</last_name>
    <phone>86-045186605180</phone>
    <email>jhb101180@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yanli Sun, Master</last_name>
    <phone>86-045186605180</phone>
    <email>289739367@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Yu, MD,PhD</last_name>
      <phone>86-045186605180</phone>
      <email>yubodr@163.com</email>
    </contact>
    <investigator>
      <last_name>Bo Yu, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Jüni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019 Jan 7;40(2):87-165. doi: 10.1093/eurheartj/ehy394. Erratum in: Eur Heart J. 2019 Oct 1;40(37):3096.</citation>
    <PMID>30165437</PMID>
  </reference>
  <reference>
    <citation>Jeger RV, Farah A, Ohlow MA, Mangner N, Möbius-Winkler S, Leibundgut G, Weilenmann D, Wöhrle J, Richter S, Schreiber M, Mahfoud F, Linke A, Stephan FP, Mueller C, Rickenbacher P, Coslovsky M, Gilgen N, Osswald S, Kaiser C, Scheller B; BASKET-SMALL 2 Investigators. Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. Lancet. 2018 Sep 8;392(10150):849-856. doi: 10.1016/S0140-6736(18)31719-7. Epub 2018 Aug 28.</citation>
    <PMID>30170854</PMID>
  </reference>
  <reference>
    <citation>Vos NS, Dirksen MT, Vink MA, van Nooijen FC, Amoroso G, Herrman JP, Kiemeneij F, Patterson MS, Slagboom T, van der Schaaf RJ. Safety and feasibility of a PAclitaxel-eluting balloon angioplasty in Primary Percutaneous coronary intervention in Amsterdam (PAPPA): one-year clinical outcome of a pilot study. EuroIntervention. 2014 Sep;10(5):584-90. doi: 10.4244/EIJV10I5A101.</citation>
    <PMID>25256200</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 10, 2021</study_first_submitted>
  <study_first_submitted_qc>June 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Second Affiliated Hospital of Harbin Medical University</investigator_affiliation>
    <investigator_full_name>Yu Bo</investigator_full_name>
    <investigator_title>The Head of cardiology department</investigator_title>
  </responsible_party>
  <keyword>Drug-Coated Balloon</keyword>
  <keyword>De-novo Lesions</keyword>
  <keyword>Acute Coronary Syndromes</keyword>
  <keyword>DCB-ACS</keyword>
  <keyword>ACS</keyword>
  <keyword>DCB</keyword>
  <keyword>Clinical Trial</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

